University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology
|
|
- Hilda Stewart
- 5 years ago
- Views:
Transcription
1 University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology This material is supported in part by unrestricted educational grants from: Abbott, Bayer HealthCare, Merck Frosst, Roche Diagnostics, and Wyeth
2
3 Table of Contents Page Introduction Antibiogram Resistance Trends List of Medically Relevant Microorganisms Abbreviations for Antimicrobial Agents Antibiogram Gram-negative Tables Acinetobacter baumanii complex. 10 Burkholderia cepacia complex Citrobacter freundii complex Citrobacter koseri Enterobacter aerogenes Enterobacter cloacae Escherichia coli (including ESBLs) Haemophilus influenzae Klebsiella species (including ESBLs ). 15 Morganella morganii Proteus mirabilis.. 16 Pseudomonas aeruginosa Serratia marcesens Stenotrophomonas maltophilia Gram-positive Tables Enterococcus species (including VRE) Staphylococcus aureus (methicillin susceptible; MSSA) 20 Staphylococcus aureus (methicillin resistant; MRSA) 21 Staphylococcus species, coagulase-negative Staphylococcus lugdunensis Viridans group streptococci. 23 Streptococcus anginosis group 23 Streptococcus pneumoniae Streptococcus pyogenes Candida species
4 Table of Contents 2007 Antibiogram Page Gram-negative Tables Acinetobacter baumanii complex. 27 Burkholderia cepacia complex Citrobacter freundii complex Citrobacter koseri Enterobacter aerogenes Enterobacter cloacae Escherichia coli (including ESBLs) Haemophilus influenzae Klebsiella species (including ESBLs ). 32 Morganella morganii Proteus mirabilis.. 33 Pseudomonas aeruginosa Serratia marcesens Stenotrophomonas maltophilia Gram-positive Tables Enterococcus species (including VRE) Staphylococcus aureus (methicillin susceptible; MSSA) 37 Staphylococcus aureus (methicillin resistant; MRSA) 38 Staphylococcus species, coagulase-negative Staphylococcus lugdunensis Viridans group streptococci. 40 Streptococcus anginosis group. 40 Streptococcus pneumoniae Streptococcus pyogenes Candida species
5 Introduction The antibiogram is an annual cumulative report of the antimicrobial susceptibility rates of common microbial pathogens to antimicrobials available on the hospital formulary. This report represents the local microbial epidemiology of the University of Alberta (UAH), Stollery Childrens Hospital, and the Cross Cancer Institute (CCI), and is intended to be used as a guideline to direct empiric antimicrobial therapy. Antibiograms are generated by the compilation of susceptibility results from all first clinical isolates of a specific pathogen recovered from an individual patient per calendar year. That is, only the first isolate within a 14-day period, regardless of specimen type or body site, is selected for analysis. The rationale for this referral period is based on the need to represent wild-type susceptibility profiles and avoid over-representing antimicrobial resistance that may develop de novo during a patient s prolonged hospital stay. Susceptibility rates for patient groups (ie. age or ward location) represented by less than 10 isolates of a pathogen were not calculated due to the limited statistical relevance; in fact, rates derived from less than 30 isolates are of limited statistical value and should be interpreted carefully. This antibiogram handbook contains summary data for the years 2008 and 2007, presented in that order. Notable antimicrobial resistance trends are summarized below and are also included as footnotes after appropriate antibiogram tables. A tremendous amount of effort goes into the creation of this document each year and the effort of the entire medical microbiology technologist staff is truly appreciated. In particular, we would like to acknowledge Linda Rosmus, Joyce Rushton, Stacey Vachon, and Sophie Chlebek, for their sizable contributions. Also, we would like to acknowledge Dr. Darren Hudson, UAH, for taking a lead role in the development of turnkey electronic approach to the antibiogram data analyses that has significantly improved the time and effort required for the production of this document. The antibiogram is available in PDF format on the Department of Laboratory Medicine and Pathology websites below: A CD-ROM application for handheld electronic devices has also been made available through Dr. Darren Hudson, RADogs Productions Inc., and the kind support of Wyeth. Inquiries and feedback may be directed to Dr. Jeff Fuller, Division of Medical Microbiology, at jeff.fuller@capitalhealth.ca. 4
6 Antibiogram Resistance Trends Enterobacteriaceae: Enterobacter, Citrobacter, and Serratia species may develop broad-spectrum β-lactam resistance during prolonged therapy. This resistance phenotype may develop during β-lactam therapy and confers resistance to all β-lactams except for imipenem and meropenem. These pathogens are also intrinsically resistant to ampicillin, cefazolin, and cefuroxime. The extended-spectrum β-lactamase (ESBL) resistance phenotype confers resistance to all third-generation cephalosporins and, in many cases, piperacillin-tazobactam. ESBL-positive Escherichia coli isolation rates have increased significantly in the last several years; <1% in 2005, 2.5% in 2006, 5.2% in 2007, and 3.6% in A significant proportion of ESBL-positive E. coli are also resistant to other antibiotic classes including the quinolones (83%), aminoglycosides (43%), and trimethoprimsulfamethoxazole (68%); 2008 data. Klebsiella ESBL prevalence also seems to be on the rise with isolation rates of 2.3%, 3.4%, and 4.2% in 2006, 2007, and 2008, respectively. Cross-resistance rates in 2008 to the quinolones, aminoglycosides, and trimethoprim-sulfamethoxazole were 31%, 28%, and 37%, respectively. Enterococcus species: Resistance rates in clinically relevant enterococci have not changed significantly over the last four years. However, periodic hospital outbreaks of vancomycin resistant enterococcus (VRE) increase the risk of serious infections with resistant erterococci. It is important to recognize that identification of enterococci to the species level is only performed for sterile site isolates but vancomycin resistance is confirmed for all clinically relevant isolates, regardless of specimen site. In 2008, resistance to vancomycin was 2%, which included 3 VRE bacteremic episodes and 29 non-sterile site isolates, primarily urine specimens. Similar findings were observed in Pseudomonas aeruginosa: Resistance rates in P. aeruginosa have remained relatively unchanged for over four years of surveillance in patients with and without cystic fibrosis and in both adult and pediatric populations. Resistance in 2008 was 14% to ceftazidime, 30% to ciprofloxacin, 27% to gentamicin, 22% to imipenem, and 12% to piperacillin. 5
7 Staphylococcus aureus: Resistance and isolation rates of S. aureus (ie. MSSA) remain relatively stable. However, the prevalence of methicillinresistant S.aureus (MRSA) isolates, which are resistant to all β-lactam antibiotics, has increased over the past several years. MRSA strains may be referred to as community-associated (CA) or hospital-associated (HA) which, in the context of this antibiogram, primarily differ based on the degree of non-β-lactam antibiotic resistance. CA-MRSA tend to be more predictably susceptible to clindamycin, gentamicin, and trimethoprim-sulphamethoxazole than HA-MRSA but this distinction technically requires molecular genotyping that is not routinely available. The annual isolation rate of MRSA relative to all S. aureus from 2004 to 2008 was 4%, 7%, 18%, 25%, and 28%, respectively. In 2008, 529 (470 Adult, 59 Pediatric) MRSA isolates were identified with susceptibility testing but genotype data is available only for the subset displayed in the table; no linezolid resistance and only one isolate with intermediate vancomycin resistance (VISA) were detected. Similarly, 438 (414 Adult, 24 Pediatric) MRSA were identified in 2007 and all were susceptible to linezolid and vancomycin. CA-MRSA resistance to clindamycin was 12% in 2007 (n=73) and increased to 29% in 2008 (n=100) while resistance to gentamicin and trimethoprim-sulphamethoxazole in remained less than 5%, similar to MSSA. Streptococcus pneumoniae: As of 2008, penicillin susceptibility interpretations for all pneumococcal isolates are reported in three categories to account for penicillin pharmacodynamics in cases of meningitis, non-meningeal infections, or oral penicillin V therapy; resistance for 2008 was 14%, 4%, and 14%, respectively. Similarly, ceftriaxone rates for meningeal and non-meningeal infections were 6% and 2%, respectively. Note, these rates do not reflect actual cases of pneumococcal meningitis. Resistance to the macrolides in S. pneumoniae is a global problem; Canadian rates have been steadily increasing for the past decade and reached ~25% in This is mirrored by our hospital rate, which has increased from 14% in 2006, to 20% in 2007, to 26% in No vancomycin resistance has been detected to date in S. pneumoniae. Trimethoprimsulphamethoxazole resistance has remained stable at ~25% for the last several years and quinolone resistance is rare. Candida species: C. albicans and C. glabrata comprise more than 80% of all Candida isolated from sterile-sites. This has remained unchanged since 2005 when UAH yeast susceptibility results were first published. C. albicans are predictably susceptible to most antifungal agents. However, C. glabrata exhibit significant resistance to fluconazole (30%), which is consistent with global resistance rates. 6
8 Medically Relevant Pathogens Based on Gram Morphology Gram-negative bacilli Lactose Fermenters Non-lactose Fermenters Glucose Non-fermenters Escherichia coli Serratia marcescens Pseudomonas aeruginosa Klebsiella pneumoniae Proteus mirabilis Pseudomonas species Klebsiella oxytoca Morganella morganii Stenotrophomonas maltophilia Enterobacter cloacae Aeromonas species Acinetobacter baumanii complex Citrobacter freundii complex Providencia rettgeri Achromobacter species Enterobacter aerogenes Providencia stuartii Burkholderia cepacia Citrobacter koseri Salmonella species Chryseobacterium species Gram-positive Cocci Gram-positive Cocci in Chains Enterococcus species Streptococcus species, including: Streptococcus pyogenes (Group A) Streptococcus agalactiae (Group B) Streptococcus pneumoniae Viridans group streptococci Streptococcus anginosus group Gram-positive Cocci in Clumps Staphylococcus aureus Staphylococcus species, coagulase-negative Staphylococcus lugdunensis Micrococcus species Aerococcus species Rothia mucilaginosus 7
9 Abbreviation Glossary for Antimicrobials Antimicrobial Abbreviation Antimicrobial Abbreviation Amikacin AMK Gentamicin GEN Ampicillin AMP Gentamicin Synergy GM500 Amphotericin B AMB Imipenem IMI Caspofungin CASP Levofloxacin LEV Cefazolin FAZ Linezolid LNZ Ceftriaxone CRO Meropenem MERO Ceftazidime CAZ Nitrofurantoin NIT Cefuroxime CXM Penicillin PEN Ciprofloxacin CIP Pipercillin PIP Clindamycin CLIN Rifampin RIF Cloxacillin CLOX Tetracycline TET Colistin COL Ticarcillin-clavulanic acid TIM Doxycycline DOXY Tobramycin TOB Erythromycin ERY Trimethoprim-sulfamethoxazole SXT Fluconazole FLUC Vancomycin VAN Flucytosine 5-FC Voriconazole VORI 8
10 University of Alberta Hospital Antibiogram Antibiogram Tables 9
11 University of Alberta Hospital Antibiogram 2008 Acinetobacter baumanni complex All Specimen Sources CAZ CIP COL GEN IMI TOB SXT % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED Burkholderia cepacia complex All Specimen Sources CAZ CIP GEN IMI MERO PIP SXT CF Patients % SUS ALL Ages # SUS # TESTED
12 University of Alberta Hospital Antibiogram 2008 Citrobacter freundii complex % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED Citrobacter koseri % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED Enterobacter, Citrobacter, and Serratia species may develop broad-spectrum β-lactam resistance during prolonged therapy. This resistance phenotype may develop during β-lactam therapy and confers resistance to all β-lactams except for imipenem and meropenem. These pathogens are also intrinsically resistant to ampicillin, cefazolin, and cefuroxime. 11
13 University of Alberta Hospital Antibiogram 2008 Enterobacter aerogenes % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED Enterobacter cloacae All Patients % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED % SUS UAH 3C3/3C4 # SUS # TESTED Enterobacter, Citrobacter, and Serratia species may develop broad-spectrum β-lactam resistance during prolonged therapy. This resistance phenotype may develop during β-lactam therapy and confers resistance to all β-lactams except for imipenem and meropenem. These pathogens are also intrinsically resistant to ampicillin, cefazolin, and cefuroxime. 12
14 University of Alberta Hospital Antibiogram 2008 Escherichia coli All Patients % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED % SUS UAH 3C3/3C4 # SUS # TESTED % SUS CCI # SUS # TESTED Escherichia coli - ESBL Producers % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED The extended-spectrum β-lactamase (ESBL) resistance phenotype confers resistance to all third-generation cephalosporins and, in many cases, piperacillin-tazobactam. ESBL-positive E. coli isolation rates have increased significantly in the last several years; <1% in 2005, 2.5% in 2006, 5.2% in 2007, and 3.6% in A significant number of ESBL E. coli are also resistant to other antibiotic classes including quinolones (83%), aminoglycosides (43%), and trimethoprim-sulfamethoxazole (68%); 2008 data. 13
15 University of Alberta Hospital Antibiogram 2008 Haemophilus influenzae All Specimen Sources AMP CRO CXM SXT % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED
16 University of Alberta Hospital Antibiogram 2008 Klebsiella species All Patients % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED % SUS UAH 3C3/3C4 # SUS # TESTED % SUS CCI # SUS # TESTED Klebsiella species - ESBL Producers % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED The extended-spectrum β-lactamase (ESBL) resistance phenotype confers resistance to all third-generation cephalosporins and, in many cases, piperacillin-tazobactam. Klebsiella ESBL prevalence seems to be on the rise with isolation rates of 2.3%, 3.4%, and 4.2% in 2006, 2007, and 2008, respectively. Cross-resistance rates in 2008 to the quinolones, aminoglycosides, and trimethoprim-sulfamethoxazole were 31%, 28%, and 37%, respectively. 15
17 University of Alberta Hospital Antibiogram 2008 Morganella morganii % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED Proteus mirabilis % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED
18 University of Alberta Hospital Antibiogram 2008 Pseudomonas aeruginosa All Specimen Sources AMK CAZ CIP GEN IMI MERO PIP TOB All Patients % SUS # SUS ALL Ages # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED Non-CF Patients % SUS ALL Ages # SUS # TESTED % SUS >17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED CF Patients % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED UAH 3C3/3C4 % SUS # SUS # TESTED Resistance rates in P. aeruginosa have remained relatively unchanged for over four years of surveillance in patients with and without cystic fibrosis and in both adult and paediatric populations. 17
19 University of Alberta Hospital Antibiogram 2008 Serratia marcescens % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED Enterobacter, Citrobacter, and Serratia species may develop broad-spectrum β-lactam resistance during prolonged therapy. This resistance phenotype may develop during β-lactam therapy and confers resistance to all β-lactams except for imipenem and meropenem. These pathogens are also intrinsically resistant to ampicillin, cefazolin, and cefuroxime. Stenotrophomonas maltophilia All Specimen Sources DOXY TIM SXT All Patients % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED % SUS UAH 3C3/3C4 # SUS # TESTED
20 University of Alberta Hospital Antibiogram 2008 Enterococcus species All Specimen Sources AMP CIP GM500 LNZ NIT VAN All Patients % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED % SUS UAH 3C3/3C4 # SUS # TESTED % SUS CCI # SUS # TESTED Enterococcus faecalis Blood Specimens AMP CIP GM500 LNZ NIT* VAN % SUS ALL Ages # SUS # TESTED Enterococcus faecium Blood Specimens AMP CIP GM500 LNZ NIT* VAN % SUS ALL Ages # SUS # TESTED *, for urninary tract infections only Resistance rates in enterococci have not changed significantly over the last four years. However, the potential for resistance to vancomycin (VRE) is now a much greater concern. Enterococcal species identification is only performed for sterile site isolates but vancomycin resistance is confirmed for all clinically relevant isolates, regardless of specimen site. In 2008, resistance to vancomycin was 2%, which included 3 VRE bacteremic episodes and 29 non-sterile site isolates, primarily urine specimens. Similar findings were observed in
21 University of Alberta Hospital Antibiogram 2008 Staphylococcus aureus - MSSA All Specimen Sources CIP CLIN CLOX ERY GEN LNZ NIT RIF SXT TET VAN All Patients % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED % SUS UAH 3C3/3C4 # SUS # TESTED % SUS UAH 3C2 # SUS # TESTED % SUS CCI # SUS # TESTED
22 University of Alberta Hospital Antibiogram 2008 Staphylococcus aureus - MRSA All Specimen Sources CIP CLIN CLOX ERY GEN LNZ NIT RIF SXT TET VAN % SUS Community-associated # SUS # TESTED % SUS Hospital-associated # SUS # TESTED Resistance and isolation rates of S. aureus (ie. MSSA) remain relatively stable. However, the prevalence of methicillin-resistant S.aureus (MRSA) isolates, which are resistant to all β-lactam antibiotics, has increased over the past several years. MRSA strains may be referred to as communityassociated (CA) or hospital-associated (HA) which, in the context of this antibiogram, primarily differ based on the degree of non-β-lactam antibiotic resistance. CA-MRSA tend to be more predictably susceptible to clindamycin, gentamicin, and trimethoprim-sulphamethoxazole than HA- MRSA but this distinction technically requires molecular genotyping that is not routinely available. The annual isolation rate of MRSA relative to all S. aureus from 2004 to 2008 was 4%, 7%, 18%, 25%, and 28%, respectively. In 2008, 529 (470 Adult, 59 Pediatric) MRSA isolates were identified with susceptibility testing but genotype data is available only for the subset displayed in the table; no linezolid resistance and only one isolate with intermediate vancomycin resistance (VISA) were detected. Similarly, 438 (414 Adult, 24 Pediatric) MRSA were identified in 2007 and all were susceptible to linezolid and vancomycin. CA-MRSA resistance to clindamycin was 12% in 2007 (n=73) and increased to 29% in 2008 (n=100) while resistance to gentamicin and trimethoprim-sulphamethoxazole in remained less than 5%, similar to MSSA. 21
23 University of Alberta Hospital Antibiogram 2008 Staphylococcus species, coagulase-negative All Specimen Sources FAZ CIP CLIN CLOX ERY GEN NIT PEN SXT VAN All Patients % SUS ALL Ages # SUS # TESTED % SUS > 17 years old # SUS # TESTED % SUS UAH 3C3/3C4 < 17 years old # SUS # TESTED % SUS # SUS # TESTED Staphylococcus lugdunensis All Specimen Sources FAZ CIP CLIN CLOX ERY GEN NIT PEN SXT VAN % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED
24 University of Alberta Hospital Antibiogram 2008 Viridans Group Streptococci All Specimen Sources CRO PEN VAN ALL Ages > 17 years < 17 years % SUS # SUS # TESTED % SUS # SUS # TESTED % SUS # SUS # TESTED Streptococcus anginosis group All Specimen Sources CRO PEN VAN % SUS ALL Ages # SUS # TESTED
25 University of Alberta Hospital Antibiogram 2008 Streptococcus pneumoniae CRO CRO DOXY ERY LEV MERO PEN PEN PEN SXT VAN All Specimen Sources (M) (NM) (M) (NM) (PO) All Patients % SUS ALL Ages # SUS # TESTED % SUS > 17 years old # SUS # TESTED % SUS < 17 years old # SUS UAH 3C3/3C4 M, meningitis; NM, non-meningitis; PO, oral administration. # TESTED % SUS # SUS # TESTED As of 2008, penicillin susceptibility interpretations for all pneumococcal isolates are reported in three categories to account for penicillin pharmacodynamics in cases of meningitis, non-meningeal infections, or oral penicillin V therapy; resistance for 2008 was 14%, 4%, and 14%, respectively. Similarly, ceftriaxone rates for meningeal and non-meningeal infections were 6% and 2%, respectively. Note, these rates do not reflect actual cases of pneumococcal meningitis. Resistance to the macrolides in S. pneumoniae is a global problem; Canadian rates have been steadily increasing for the past decade and reached ~25% in This is mirrored by our hospital rate, which has increased from 14% in 2006, to 20% in 2007, to 26% in No vancomycin resistance has been detected to date in S. pneumoniae. Trimethoprim-sulphamethoxazole resistance has remained stable at ~25% for the last several years and quinolone resistance is rare. Streptococcus pyogenes All Specimen Sources CLIN ERY PEN % SUS ALL Ages # SUS # TESTED
26 University of Alberta Hospital Antibiogram 2008 Candida species All Specimen Sources AMB 5-FC ITRA FLUC VORI CASP C. albicans % SUS ALL Ages # SUS # TESTED C. glabrata % SUS ALL Ages # SUS # TESTED C. parapsilosis % SUS ALL Ages # SUS # TESTED C. tropicalis % SUS ALL Ages # SUS # TESTED C. albicans and C. glabrata comprise more than 80% of all Candida isolated from sterile-sites. This has remained unchanged since 2005 when UAH yeast susceptibility results were first published. C. albicans are predictably susceptible to most antifungal agents. However, C. glabrata exhibit significant resistance to fluconazole (30%), which is consistent with global resistance rates. 25
27 University of Alberta Hospital Antibiogram Antibiogram Tables 26
28 University of Alberta Hospital Antibiogram 2007 Acinetobacter baumanni complex All Specimen Sources CAZ CIP COL GEN IMI TOB SXT % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED Burkholderia cepacia complex All Specimen Sources CAZ CIP GEN IMI MERO PIP SXT CF Patients % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED
29 University of Alberta Hospital Antibiogram 2007 Citrobacter freundii complex % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED Citrobacter koseri % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED Enterobacter, Citrobacter, and Serratia species may develop broad-spectrum β-lactam resistance during prolonged therapy. This resistance phenotype may develop during β-lactam therapy and confers resistance to all β-lactams except for imipenem and meropenem. These pathogens are also intrinsically resistant to ampicillin, cefazolin, and cefuroxime. 28
30 University of Alberta Hospital Antibiogram 2007 Enterobacter aerogenes % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED Enterobacter cloacae All Patients % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED % SUS UAH 3C3/3C4 # SUS # TESTED Enterobacter, Citrobacter, and Serratia species may develop broad-spectrum β-lactam resistance during prolonged therapy. This resistance phenotype may develop during β-lactam therapy and confers resistance to all β-lactams except for imipenem and meropenem. These pathogens are also intrinsically resistant to ampicillin, cefazolin, and cefuroxime. 29
31 University of Alberta Hospital Antibiogram 2007 Escherichia coli All Patients % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED % SUS UAH 3C3/3C4 # SUS # TESTED % SUS CCI # SUS # TESTED Escherichia coli - ESBL Producers % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED The extended-spectrum β-lactamase (ESBL) resistance phenotype confers resistance to all third-generation cephalosporins and, in many cases, piperacillin-tazobactam. ESBL-positive E. coli isolation rates have increased significantly in the last several years; <1% in 2005, 2.5% in 2006, 5.2% in 2007, and 3.6% in A significant number of ESBL E. coli are also resistant to other antibiotic classes including quinolones (83%), aminoglycosides (43%), and trimethoprim-sulfamethoxazole (68%); 2008 data. 30
32 University of Alberta Hospital Antibiogram 2007 Haemophilus influenzae All Specimen Sources AMP CRO CXM SXT % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED
33 University of Alberta Hospital Antibiogram 2007 Klebsiella species All Patients % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED % SUS UAH 3C3/3C4 # SUS # TESTED % SUS CCI # SUS # TESTED Klebsiella species - ESBL Producers % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED The extended-spectrum β-lactamase (ESBL) resistance phenotype confers resistance to all third-generation cephalosporins and, in many cases, piperacillin-tazobactam. Klebsiella ESBL prevalence seems to be on the rise with isolation rates of 2.3%, 3.4%, and 4.2% in 2006, 2007, and 2008, respectively. Cross-resistance rates in 2008 to the quinolones, aminoglycosides, and trimethoprim-sulfamethoxazole were 31%, 28%, and 37%, respectively. 32
34 University of Alberta Hospital Antibiogram 2007 Morganella morganii % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED Proteus mirabilis % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED
35 University of Alberta Hospital Antibiogram 2007 Pseudomonas aeruginosa All Specimen Sources AMK CAZ CIP GEN IMI MERO PIP TOB All Patients % SUS # SUS ALL Ages # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED Non-CF Patients % SUS ALL Ages # SUS # TESTED % SUS >17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED CF Patients % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED UAH 3C3/3C4 % SUS # SUS # TESTED Resistance rates in P. aeruginosa have remained relatively unchanged for over four years of surveillance in patients with and without cystic fibrosis and in both adult and paediatric populations. 34
36 University of Alberta Hospital Antibiogram 2007 Serratia marcescens All Patients % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED Enterobacter, Citrobacter, and Serratia species may develop broad-spectrum β-lactam resistance during prolonged therapy. This resistance phenotype may develop during β-lactam therapy and confers resistance to all β-lactams except for imipenem and meropenem. These pathogens are also intrinsically resistant to ampicillin, cefazolin, and cefuroxime. Stenotrophomonas maltophilia All Specimen Sources DOXY TIM SXT All Patients % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED % SUS UAH 3C3/3C4 # SUS # TESTED
37 University of Alberta Hospital Antibiogram 2007 Enterococcus species All Specimen Sources AMP CIP GM500 LNZ NIT VAN All Patients % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED % SUS UAH 3C3/3C4 # SUS # TESTED % SUS CCI # SUS # TESTED Enterococcus faecalis Blood Specimens AMP CIP GM500 LNZ NIT* VAN % SUS ALL Ages # SUS # TESTED Enterococcus faecium Blood Specimens AMP CIP GM500 LNZ NIT* VAN % SUS ALL Ages # SUS # TESTED *, for urninary tract infections only Resistance rates in enterococci have not changed significantly over the last four years. However, the potential for resistance to vancomycin (VRE) is now a much greater concern. Enterococcal species identification is only performed for sterile site isolates but vancomycin resistance is confirmed for all clinically relevant isolates, regardless of specimen site. In 2008, resistance to vancomycin was 2%, which included 3 VRE bacteremic episodes and 29 non-sterile site isolates, primarily urine specimens. Similar findings were observed in
38 University of Alberta Hospital Antibiogram 2007 Staphylococcus aureus MSSA All Specimen Sources FAZ CIP CLIN CLOX ERY GEN LNZ NIT PEN SXT VAN All Patients % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED % SUS < 17 years # SUS # TESTED % SUS UAH 3C3/3C4 # SUS # TESTED % SUS UAH 3C2 # SUS # TESTED % SUS CCI # SUS # TESTED
39 University of Alberta Hospital Antibiogram 2007 Staphylococcus aureus - MRSA All Specimen Sources CIP CLIN CLOX ERY GEN LNZ NIT RIF TET SXT VAN % SUS Community-associated # SUS # TESTED % SUS Hospital-associated # SUS # TESTED Resistance and isolation rates of S. aureus (ie. MSSA) remain relatively stable. However, the prevalence of methicillin-resistant S.aureus (MRSA) isolates, which are resistant to all β-lactam antibiotics, has increased over the past several years. MRSA strains may be referred to as communityassociated (CA) or hospital-associated (HA) which, in the context of this antibiogram, primarily differ based on the degree of non-β-lactam antibiotic resistance. CA-MRSA tend to be more predictably susceptible to clindamycin, gentamicin, and trimethoprim-sulphamethoxazole than HA- MRSA but this distinction technically requires molecular genotyping that is not routinely available. The annual isolation rate of MRSA relative to all S. aureus from 2004 to 2008 was 4%, 7%, 18%, 25%, and 28%, respectively. In 2008, 529 (470 Adult, 59 Pediatric) MRSA isolates were identified with susceptibility testing but genotype data is available only for the subset displayed in the table; no linezolid resistance and only one isolate with intermediate vancomycin resistance (VISA) were detected. Similarly, 438 (414 Adult, 24 Pediatric) MRSA were identified in 2007 and all were susceptible to linezolid and vancomycin. CA-MRSA resistance to clindamycin was 12% in 2007 (n=73) and increased to 29% in 2008 (n=100) while resistance to gentamicin and trimethoprim-sulphamethoxazole in remained less than 5%, similar to MSSA. 38
40 University of Alberta Hospital Antibiogram 2007 Staphylococcus species, coagulase-negative All Specimen Sources FAZ CIP CLIN CLOX ERY GEN NIT PEN SXT VAN All Patients % SUS ALL Ages # SUS # TESTED % SUS > 17 years old # SUS # TESTED % SUS UAH 3C3/3C4 < 17 years old # SUS # TESTED % SUS # SUS # TESTED Staphylococcus lugdunensis All Specimen Sources FAZ CIP CLIN CLOX ERY GEN NIT PEN SXT VAN % SUS ALL Ages # SUS # TESTED % SUS > 17 years # SUS # TESTED
41 University of Alberta Hospital Antibiogram 2007 Viridans Group Streptococci All Specimen Sources CRO PEN VAN ALL Ages > 17 years < 17 years % SUS # SUS # TESTED % SUS # SUS # TESTED % SUS # SUS # TESTED Streptococcus anginosis group All Specimen Sources CRO PEN VAN % SUS ALL Ages # SUS # TESTED
42 University of Alberta Hospital Antibiogram 2007 Streptococcus pneumoniae All Specimen Sources CRO ERY LEV MERO PEN SXT VAN All Patients % SUS ALL Ages # SUS # TESTED % SUS > 17 years old # SUS # TESTED % SUS UAH 3C3/3C4 < 17 years old # SUS # TESTED % SUS # SUS # TESTED As of 2008, penicillin susceptibility interpretations for all pneumococcal isolates are reported in three categories to account for penicillin pharmacodynamics in cases of meningitis, non-meningeal infections, or oral penicillin V therapy; resistance for 2008 was 14%, 4%, and 14%, respectively. Similarly, ceftriaxone rates for meningeal and non-meningeal infections were 6% and 2%, respectively. Note, these rates do not reflect actual cases of pneumococcal meningitis. Resistance to the macrolides in S. pneumoniae is a global problem; Canadian rates have been steadily increasing for the past decade and reached ~25% in This is mirrored by our hospital rate, which has increased from 14% in 2006, to 20% in 2007, to 26% in No vancomycin resistance has been detected to date in S. pneumoniae. Trimethoprim-sulphamethoxazole resistance has remained stable at ~25% for the last several years and quinolone resistance is rare. Streptococcus pyogenes All Specimen Sources CLIN ERY PEN % SUS ALL Ages # SUS # TESTED
43 University of Alberta Hospital Antibiogram 2007 Candida species All Specimen Sources AMB 5-FC ITRA FLUC VORI CASP C. albicans % SUS ALL Ages # SUS # TESTED C. glabrata % SUS ALL Ages # SUS # TESTED C. parapsilosis % SUS ALL Ages # SUS # TESTED C. tropicalis % SUS ALL Ages # SUS # TESTED C. albicans and C. glabrata comprise more than 80% of all Candida isolated from sterile-sites. This has remained unchanged since 2005 when UAH yeast susceptibility results were first published. C. albicans are predictably susceptible to most antifungal agents. However, C. glabrata exhibit significant resistance to fluconazole (30%), which is consistent with global resistance rates. 42
This material is supported in part by unrestricted educational grants from: Abbott, Bayer HealthCare, Merck Frosst, Roche Diagnostics, and Wyeth Inc.
Division of Medical Microbiology Department of Laboratory Medicine and Pathology University of Alberta Hospital and Stollery Children's Hospital Antibiogram 2006 This material is supported in part by unrestricted
More informationSep Oct Nov Dec Total
LB PAGE 2 LB PAGE 3 Sep Oct Nov Dec 2007 2007 2007 2007 Total Repeat Information Total Repeats 35 15 17 9 76 Repeat Rate 6.01% 0.17% 1.12% 0.39% 2.07% Repeat Chemistry 25 0 2 0 27 Repeat Extraction 1 0
More informationLaboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator
Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18
More informationExpert rules in antimicrobial susceptibility testing: State of the art
Expert rules in antimicrobial susceptibility testing: State of the art ESCMID Postgraduate Education Course Antimicrobial Susceptibility Testing and Surveillance: from Laboratory to Clinic Hospital Universitario
More informationHUSRES Annual Report 2009 Martti Vaara
HUSRES Annual Report 2009 Martti Vaara www.huslab.fi www.intra.hus.fi Martti Vaara, 2/2010 1 The basis of this HUSRES 2009 report is the HUSLAB/Whonet database 2009, which contains susceptibility data
More informationAntibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005)
Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005) Streptococcus pneumoniae (SP) Blood Culture Isolates Penicillin intermediate Penicillin Cefotaxime 336
More informationCefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationCefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the
More informationPREVENTIVE MEDICINE - LABORATORY
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2014 vol. 118, no. 3 PREVENTIVE MEDICINE - LABORATORY ORIGINAL PAPERS CLINICAL EPIDEMIOLOGICAL STUDY ON THE INCIDENCE OF ESCHERICHIA COLI INFECTIONS IN THE CANCER PATIENTS
More informationSurveillance for Central Line Associated Blood Stream Infections (CLABSI) in Intensive Care Units
Canadian Nosocomial Infection Surveillance Program Surveillance for Central Line Associated Blood Stream Infections (CLABSI) in Intensive Care Units 2017 CLABSI Surveillance Protocol Revised November 7
More informationDIVISION OF ANTIINFECTIVE DRUG PRODUCTS (HFD-520) CLINICAL MICROBIOLOGY REVIEW NDA Date review completed: 15 Jun 05
Date company submitted: 15 Dec 04 Date received by CDER: 15 Dec 04 Reviewer: Fred Marsik, Ph.D. Date assigned: 15 Dec 04 NAME AND ADDRESS OF APPLICANT Wyeth Pharmaceuticals Inc. P.O. Box 8299 Philadelphia,
More informationTigecycline activity tested against 26, 474 bloodstream infection isolates: a collection from 6 continents
Diagnostic Microbiology and Infectious Disease 52 (2005) 181 186 www.elsevier.com/locate/diagmicrobio Tigecycline activity tested against 26, 474 bloodstream infection isolates: a collection from 6 continents
More informationSusceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011)
b r a z j i n f e c t d i s. 2 0 1 3;1 7(6):672 681 The Brazilian Journal of INFECTIOUS DISEASES www.elsevier.com/locate/bjid Original article Susceptibility rates in Latin American nations: report from
More informationAntimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2005, p. 3501 3512 Vol. 49, No. 8 0066-4804/05/$08.00 0 doi:10.1128/aac.49.8.3501 3512.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationKENNEL KARE SC DISINFECTANT / CLEANER / DEODORIZER Efficacy Data EPA Reg. #
Inc. Efficacy: Hospital Disinfection (at ½ ounce per gallon) Kennel Kare SC is bactericidal according to the AOAC Use Dilution Test method on hard inanimate surfaces modified in the presence of 5% organic
More informationAuthor: Souha Kanj Andrew Whitelaw Michael J. Dowzicky. To appear in: International Journal of Antimicrobial Agents
t Title: In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011 Author: Souha Kanj Andrew Whitelaw
More informationCeftomax TM S (Cefoperazone Sodium plus Sulbactam Sodium Injection)
COMPOSITION Ceftomax TM S (Cefoperazone Sodium plus Sulbactam Sodium Injection) CEFTOMAX - S Injection 1.5 gm Each vial contains: Cefoperazone Sodium equivalent to Cefoperazone IP. 1,000 mg Sulbactam Sodium
More informationKENNEL KARE SC DISINFECTANT / CLEANER / DEODORIZER Efficacy Data EPA Reg. #
Inc. Efficacy: Disinfection (at ½ ounce per gallon) Kennel Kare SC is bactericidal according to the AOAC Use Dilution Test method on hard inanimate surfaces modified in the presence of 5% organic serum
More informationCanadian Nosocomial Infection Surveillance Program 2017 SURVEILLANCE OF SURGICAL SITES INFECTIONS FOLLOWING PEDIATRIC CARDIAC SURGERY
Canadian Nosocomial Infection Surveillance Program 2017 SURVEILLANCE OF SURGICAL SITES INFECTIONS FOLLOWING PEDIATRIC CARDIAC SURGERY December 29, 2016 FINAL Working Group: Bonita Lee (Chair), Joanne Langley,
More informationHelen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); July 2014.
Annual survey of extended-spectrum -lactamase (ESBL)-producing Enterobacteriaceae, 2013 Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research
More informationDiscussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category
Discussion points 2009 CLSI M100 S19 Update Nebraska Public Health Laboratory Changes most important to routine antimicrobial susceptibility testing. Documents available Janet Hindler discussion slide
More informationConsultation on the Revision of Carbapenem Breakpoints
Consultation on the Revision of Carbapenem Breakpoints July 2018 Please send comments to the EUCAST Scientific Secretary at jturnidge@gmail.com by September 15. EUCAST revision of carbapenem breakpoints
More informationTranslocation Studies Mid-Term Review (MTR) Meeting Marseille, France
Marie Curie Actions Research Training Networks (RTN) Translocation Studies Mid-Term Review (MTR) Meeting Marseille, France F. Vidal-Aroca, M.G.P. Page and J. Dreier Background Deteriorating situation regarding
More informationSupplemental Digital Content
Rapid Diagnosis of Infection in the Critically Ill (RADICAL), a multicenter study of molecular detection in bloodstream infections, pneumonia and sterile site infections Jean-Louis Vincent, David Brealey,
More informationExpert rules. for Gram-negatives
Academic Perspective in Expert rules Emerging Issues of Resistance in Gram-ve Bacteria for Gram-negatives Trevor Winstanley Sheffield Teaching Hospitals Presented on behalf of David Livermore University
More informationSurveillance of Healthcare Associated Infections in Scottish Intensive Care Units
Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units Annual report of data from January 2010 to December 2010 Scottish Intensive Care Society Audit Group 1 Health Protection
More informationNational Surveillance of Nosocomial Septicemia (Hospital-wide)
National Surveillance of Hospital Infections National Surveillance of Nosocomial Septicemia (Hospital-wide) National analysis Data from 01/01/2008 to 31/12/2008 1. SUMMARY BY QUARTER Quarter Patient records
More informationZINEX. Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg
ZINEX Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg Tablets Action Cefuroxime axetil owes its bactericidal activity to the parent compound cefuroxime. Cefuroxime is a well-characterized
More informationMicrosan rx Anti-Microbial Healthcare Professional Soap. Organism Positives ATCC #
: Contact Time: 30 seconds 17,500 ppm. PCMX active Organism Positives ATCC # Acinetobacter calcoaceticus var. anitratus 0 s Acinetobacter calcoaceticus var. woffii 0 s Actinobacillus pleuropneumonia 0
More informationSUPPLEMENTARY MATERIAL
SUPPLEMENTARY MATERIAL (A) Further inclusion criteria and categorisation of ICD-10 diagnostic codes Pneumonia: A310 Pulmonary mycobacterial infection A420 Pulmonary actinomycosis A481 Legionnaires' disease
More information(multidrug-resistant Pseudomonas aeruginosa; MDRP)
220 2009 (multidrug-resistant Pseudomonas aeruginosa; MDRP) 21 4 1 21 10 4 amikacin (AMK), imipenem/cilastatin (IPM), ciprofloxacin (CPFX) multidrug-resistant Pseudomonas aeruginosa (MDRP) CHROMagar TM
More informationYes No Unknown. In hospital Out of hospital Unknown. Blood Pump Drive Unit Failure External Control System Failure. Yes No Unknown
Adverse Events Device Malfunction Was there a device malfunction: Date of event: Was there a device malfunction: Major pump unit involved: Check all the apply Suspected device Thrombosis: Anticoagulant
More informationNo Need to Agonize! Tips for the Diagnosis and Treatment of Complicated UTIs
ASCENSION TEXAS No Need to Agonize! Tips for the Diagnosis and Treatment of Complicated UTIs Austin Area Society of Health-System Pharmacists April 26, 2018 Amy Carr, PharmD PGY-2 Infectious Diseases Pharmacy
More informationSpread of carbapenems resistant Enterobacteriaceae in South Africa; report from National Antimicrobial Resistance Reference Laboratory
Spread of carbapenems resistant Enterobacteriaceae in South Africa; report from National Antimicrobial Resistance Reference Laboratory Olga Perovic*, Ashika Singh-Moodley, Samantha Iyaloo 5 th November
More informationBACTERIOLOGICAL PROFILE OF DIABETIC FOOT INFECTIONS
ejpmr, 2018,5(6), 631-635 Khadse et al. SJIF Impact Factor 4.897 Research Article EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH ISSN 2394-3211 www.ejpmr.com EJPMR BACTERIOLOGICAL PROFILE OF DIABETIC
More information6. Etiology and pathogenesis of UTI
6. Etiology and pathogenesis of UTI 6.1 Bacterial profile and sensitivity pattern for UTI in our environment The treatment for urinary tract infection (UTI) will often have to be established empirically
More informationIn Vitro Activity of Ceftazidime-Avibactam Against Isolates. in a Phase 3 Open-label Clinical Trial for Complicated
AAC Accepted Manuscript Posted Online 21 November 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.01820-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10
More informationBrief Communication Clinical Microbiology
Brief Communication Clinical Microbiology Ann Lab Med 2017;37:531-535 https://doi.org/10.3343/alm.2017.37.6.531 ISSN 2234-3806 eissn 2234-3814 Comparison of a New Matrix-Assisted Laser Desorption/Ionization
More informationAdenium Biotech. Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes
Adenium Biotech Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes Board of Directors: - Stephan Christgau, PhD, chairman,
More informationUrinary Tract Infections: From Simple to Complex. Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014
Urinary Tract Infections: From Simple to Complex Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014 Learning Objectives Develop empiric antimicrobial treatment
More informationM E D I C A L L A B O R A T O R Y
M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 7 Microbiology 2017 MLE-M1 Total Commitment to Education and Service Provided by ACP, Inc. Evaluation Criteria... 2 Microbiology
More informationPrevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital
ISSN: 2319-7706 Volume 3 Number 10 (2014) pp. 474-478 http://www.ijcmas.com Original Research Article Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital
More informationUrinary Tract Infection and Pattern of Antibiotic Sensitivity in Hospitalized Patients with Diabetes Mellitus in Myanmar
Volume 2 Issue 1 2018 Page 147 to 153 Research Article Archives of Endocrinology and Diabetes Care Urinary Tract Infection and Pattern of Antibiotic Sensitivity in Hospitalized Patients with Diabetes Mellitus
More information1430 West McCoy Lane Santa Maria, CA p:
091217TR HardyCHROM BluEcoli 1 HardyCHROM Candida 2 HardyCHROM ECC 3 HardyCHROM ESBL 4 HardyCHROM Listeria 5 HardyCHROM MRSA 6 HardyCHROM O157 7 HardyCHROM Salmonella 8 HardyCHROM SS NoPRO 9 HardyCHROM
More informationEnhanced EARS-Net Surveillance 2017 First Half
1 Enhanced EARS-Net Surveillance 2017 First Half In this report Main results for 2017, first half Breakdown of factors by organism and resistance subtype Device-association Data quality assessment Key
More informationEfficacy Data. Disinfectant Cleaner & Odor Counteractant EPA REG. #
SENTS-ALE Hospital Disinfection (at 2 ounces per gallon)) Scents-Able is bactericidal according to the AOA Use Dilution Test method on hard inanimate surfaces modified in the presence of 5% organic serum
More informationPneumonia Community-Acquired Healthcare-Associated
Pneumonia Community-Acquired Healthcare-Associated Edwin Yu Clin Infect Dis 2007;44(S2):27-72 Am J Respir Crit Care Med 2005; 171:388-416 IDSA / ATS Guidelines Microbiology Principles and Practice of Infectious
More informationM E D I C A L L A B O R A T O R Y
M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 8 Microbiology 2018 MLE-M1 Total Commitment to Education and Service Provided by ACP, Inc. Evaluation Criteria... 2 Microbiology
More informationINFECTIOUS DISEASE. Page 2
Infectious disease Advantages OF TESTING INFECTIOUS DISEASE We are in the middle of a paradigm shift in infectious disease diagnostic testing. As we move from targeted infectious disease testing to a syndromic
More informationReceived 30 March 2005; returned 16 June 2005; revised 8 September 2005; accepted 12 September 2005
Journal of Antimicrobial Chemotherapy (2005) 56, 1047 1052 doi:10.1093/jac/dki362 Advance Access publication 20 October 2005 Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity,
More information/01/$ DOI: /JCM Copyright 2001, American Society for Microbiology. All Rights Reserved.
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2001, p. 183 190 Vol. 39, No. 1 0095-1137/01/$04.00 0 DOI: 10.1128/JCM.39.1.183 190.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Contemporary
More informationWhat is new in EUCAST South Africa, May, Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden
What is new in EUCAST 2016 17 South Africa, May, 2016 Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden What is new in EUCAST 2016/17? New organisms with breakpoints (Addendum 2016)
More informationAntimicrobial Resistance Surveillance Data Requirements for Priority Organisms
Antimicrobial Resistance Surveillance Data Requirements for Priority Organisms The Communicable and Infectious Disease Steering Committee Antimicrobial Resistance Surveillance Task Group Final Report to
More informationCAVIWIPES1. Technical Bulletin
CAVIWIPES1 Technical Bulletin CaviWipes1 Disinfecting Towelettes are non-woven disposable towelettes pre-saturated with CaviCide1. CaviWipes 1 are intended for use in health care settings such as hospitals,
More informationDrug Typical Dose CrCl (ml/min) Dose adjustment for renal insufficiency Acyclovir PO (HSV) 400 mg TID >10 <10 or HD PD
Antimicrobial Dosing in Renal Insufficiency (Adults) ASP Handbook * In patients on hemodialysis (), give antimicrobial immediately after dialysis on dialysis days. = Intermittent hemodialysis = Peritoneal
More informationStreptococci facultative anaerobe
THE GENUS STREPTOCOCCUS The genus Streptococcus obtains Gram-positive cocci, nonmotile, nonsporeforming, arranged mostly in chains or in pairs. Most species are facultative anaerobes. Some of streptococci
More informationDisclosure. Objectives. Evolution of β Lactamases. Extended Spectrum β Lactamases: The New Normal. Prevalence of ESBL Mystic Program
47 th Annual Meeting August 2-4, 2013 Orlando, FL Extended Spectrum β Lactamases: The New Normal Disclosure I do have a vested interest in or affiliation with the following companies or organizations Triax
More informationVITEK MS Implementation of Mass Spectrometry
VITEK MS Implementation of Mass Spectrometry Willson Jang, Technical Leader wljang@providencehealth.bc.ca Microbiology & Virology Laboratory Providence Health Care St. Paul s Hospital October 23, 2013
More informationAnnual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2016
Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2016 Sarah Gierhart and Uzo Chukwuma Approved for public release. Distribution is unlimited. The views
More informationComparative study of MALDI-TOF MS and VITEK 2 in bacteria identification
MALDI-TOF MS in Clinical Microbiology Comparative study of MALDI-TOF MS and VITEK 2 in bacteria identification Ling Guo, Liyan Ye, Qiang Zhao, Yanning Ma, Jiyong Yang, Yanping Luo Department of Microbiology,
More informationDISEASE OUTBREAKS SUMMARY
DISEASE OUTBREAKS SUMMARY Outbreaks may be defined as (a) clusters of cases related in time and place or (b) occurrence of disease above a baseline or threshold level in a defined location. In Los Angeles
More informationSUPPLEMENTAL TESTING. Tan Thean Yen
SUPPLEMETAL TESTG Tan Thean Yen To Supplement Definition: add as a supplement to what seems insufficient "supplement your diet" Why supplement? urrent methods don t work well Additional information provided
More informationPhenotypic detection of ESBLs and carbapenemases
Phenotypic detection of ESBLs and carbapenemases Standardized susceptibility testing residential workshop 2016 Katie Hopkins PhD Clinical Scientist Antimicrobial Resistance and Healthcare Associated Infections
More informationAnaerobes Bacteroides species, Clostridium species (Note: most strains of C.difficile are resistant).
CEFIXON Composition Each vial contains 1 g Ceftriaxone (as sodium). Vial Action The bactericidal activity of Ceftriaxone results from inhibition of cell wall Synthesis. Ceftriaxone has a high degree of
More informationSurveillance of Healthcare Associated Infections in Scottish Intensive Care Units
Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units Annual report of data from January 2011 to December 2011 Scottish Intensive Care Society Audit Group Health Protection
More informationHealthcare-associated infections acquired in intensive care units
SURVEILLANCE REPORT Annual Epidemiological Report for 2015 Healthcare-associated infections acquired in intensive care units Key facts In 2015, 11 788 (8.3%) of patients staying in an intensive care unit
More informationXERAVATM (eravacycline): A Novel Fluorocycline Antibacterial
XERAVATM (eravacycline): A Novel Fluorocycline Antibacterial Matteo Bassetti, MD, PhD Infectious Diseases Division University of Udine and Santa Maria Misericordia University Hospital Udine, Italy Disclosures
More informationTreatment of febrile neutropenia in patients with neoplasia
Treatment of febrile neutropenia in patients with neoplasia George Samonis MD, PhD Medical Oncologist Infectious Diseases Specialist Professor of Medicine The University of Crete, Heraklion,, Crete, Greece
More informationComparison of CPS ID 3 and CHROMagar Orientation chromogenic agars with standard biplate technique for culture of clinical urine samples
J Microbiol Immunol Infect. 2008;41:422-427 Comparison of CPS ID 3 and CHROMagar Orientation chromogenic agars with standard biplate technique for culture of clinical urine samples Jen-Chyi Chang 1,2,
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory CEFTUM TABLETS. Cefuroxime Axetil Tablets IP 125/250/500mg
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory CEFTUM TABLETS Cefuroxime Axetil Tablets IP 125/250/500mg QUALITATIVE AND QUANTITATIVE COMPOSITION CEFTUM TABLETS 125
More informationOverview of Tigecycline and Its Role in the Era of Antibiotic Resistance
BJID 2006; 10 (June) 203 Overview of Tigecycline and Its Role in the Era of Antibiotic Resistance Flávia Rossi, Denise Andreazzi University of São Paulo, LIM 03; São Paulo, SP, Brazil The increasing antimicrobial
More informationInfectious Disease Testing. UriSelect 4 Medium. Direct Identification Visibly Reliable
Infectious Disease Testing Urielect 4 Medium Direct Identification Visibly Reliable Urielect 4 Non selective chromogenic medium for the isolation, differentiation and enumeration of urinary tract infections
More informationCarbapenem Disks on MacConkey agar as screening methods for the detection of. Carbapenem-Resistant Gram negative rods in stools.
JCM Accepts, published online ahead of print on 7 November 2012 J. Clin. Microbiol. doi:10.1128/jcm.02878-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Carbapenem Disks
More informationM E D I C A L L A B O R A T O R Y
M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 5 Microbiology MLE-M1 Total Commitment to Education and Service Provided by ACP, Inc. Evaluation Criteria... 2 Microbiology
More informationPEACEHEALTH LABORATORIES
360-414-2306 www.peacehealthlabs.org Critical Values Call List - Longview Critical values are reported per the criteria published below. Laboratory results meeting these criteria indicate potential life-threatening
More informationORIGINAL ARTICLE SUSCEPTIBILITY PATTERNS IN GRAM NEGATIVE URINARY ISOLATES TO CIPROFLOXACIN, CO-TRIMOXAZOLE AND NITROFURANTOIN
SUSCEPTIBILITY PATTERNS IN GRAM NEGATIVE URINARY ISOLATES TO CIPROFLOXACIN, CO-TRIMOXAZOLE AND NITROFURANTOIN Anoop Sinha 1, Benny P V 2 HOW TO CITE THIS ARTICLE: Anoop Sinha, Benny PV. Susceptibility
More informationDORIBAX for injection
DORIBAX for injection 500 mg Powder for Intravenous Infusion NAME OF THE MEDICINE Doripenem (as monohydrate) PRODUCT INFORMATION The chemical name for doripenem monohydrate is (4R,5S,6S)-3-[((3S,5S)-5-
More informationM E D I C A L L A B O R A T O R Y
M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 5 Microbiology MLE-M2 Total Commitment to Education and Service Provided by ACP, Inc. Evaluation Criteria... 2 Microbiology
More informationM E D I C A L L A B O R A T O R Y
M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 6 Microbiology 2016 MLE-M1 Total Commitment to Education and Service Provided by ACP, Inc. Evaluation Criteria... 2 Microbiology
More informationAerobic bacteria isolated from diabetic septic wounds
Aerobic bacteria isolated from diabetic septic wounds Eithar Mohammed Mahgoub*, Mohammed Elfatih A. Omer Faculty of Pharmacy, Omdurman Islamic University Department of Pharmaceutical Microbiology, Omdurman
More informationSurveillance of Healthcare Associated Infections in Scottish Intensive Care Units
Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units Annual report of data from January - December 2012 Scottish Intensive Care Society Audit Group Health Protection Scotland
More informationAgainst Aerobic Gram-Negative Bacilli
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 1979, p. 6-6 0066-0/79/1-06/05$0.00/0 Vol., No. 6 In Vitro Activity of LY17935, a New 1-Oxa Cephalosporin, Against Aerobic Gram-Negative Bacilli DENNIS G. DELGADO,
More informationVIII Updating Course of Antimicrobials and Infectious Diseases 2018
The Author 2018. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
More informationM E D I C A L L A B O R A T O R Y
M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 3 Total Commitment to Education and Service Provided by ACP, Inc. Microbiology MLE-M2 Evaluation Criteria... 2 Microbiology
More informationUpdate on CLSI and EUCAST
Update on CLSI and EUCAST 1 Completed work» Cephalosporin breakpoints for Enterobacteriaceae ESBL screens MIC versus resistance mechanism» Carbapenem breakpoints for Enterobacteriaceae Modified Hodge Test»
More informationObjective: To assess the incidence of healthcare-associated infections (HAI) and the prevalence
Abstract Objective: To assess the incidence of healthcare-associated infections (HAI) and the prevalence of pathogens across all pediatric units within a single hospital, and trends in pediatric HAI over
More informationAffinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationNDA Briefing Document Anti-Infective Drugs Advisory Committee 05 December 2014
CEFTAZIDIME-AVIBACTAM FOR INJECTION for Treatment of Complicated Intra-abdominal Infection (used in combination with metronidazole), Complicated Urinary Tract Infection including Acute Pyelonephritis,
More informationEnhanced EARS-Net Surveillance REPORT FOR 2012 DATA
Enhanced EARS-Net Surveillance REPORT FOR DATA 1 In this report Main results for Proposed changes to the enhanced programme Abbreviations Used Here BSI Bloodstream Infections CVC Central Venous Catheter
More informationOriginal Article Clinical Microbiology INTRODUCTION
Original Article Clinical Microbiology Ann Lab Med 2015;35:416-422 http://dx.doi.org/10.3343/alm.2015.35.4.416 ISSN 2234-3806 eissn 2234-3814 Direct Identification of Urinary Tract Pathogens From Urine
More informationSepsis Treatment: Early Identification Remains the Key Issue
Sepsis Treatment: Early Identification Remains the Key Issue Marin H. Kollef, MD Professor of Medicine Washington University School of Medicine Director, Medical Critical Care Director, Respiratory Care
More informationOutbreak investigation of nosocomial infections
Definitions Outbreak investigation of nosocomial infections School of Public Health, HSUM March 2012 Walter Popp, University Clinics Essen, Germany Epidemia increased number of cases, limited in time and
More informationMethicillin-Resistant Staphylococcus aureus (MRSA) S urveillance Report 2008 Background Methods
Methicillin-Resistant Staphylococcus aureus (MRSA) Surveillance Report 2008 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services
More informationOutpatient treatment in women with acute pyelonephritis after visiting emergency department
LETTER TO THE EDITOR Korean J Intern Med 2017;32:369-373 Outpatient treatment in women with acute pyelonephritis after visiting emergency department Hee Kyoung Choi 1,*, Jin-Won Chung 2, Won Sup Oh 3,
More informationUropathogens and Host Characteristics
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 2008, p. 3980 3986 Vol. 46, No. 12 0095-1137/08/$08.00 0 doi:10.1128/jcm.00339-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Uropathogens
More informationPhenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae
ISSN: 2319-7706 Volume 4 Number 6 (2015) pp. 547-552 http://www.ijcmas.com Original Research Article Phenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae Sathya Pandurangan 1,
More informationManagement of Catheter Related Bloodstream Infection (CRBSI), including Antibiotic Lock Therapy.
Management of Catheter Related Bloodstream Infection (CRBSI), including Antibiotic Lock Therapy. Written by: Dr K Gajee, Consultant Microbiologist Date: June 2017 Approved by: Drugs & Therapeutics Committee
More informationRecommendations for Dilution Susceptibility Testing Concentrations of the Cefoperazone-Sulbactam Combination
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 1987. p. 1725-1729 0095-1137/87/091725-05$02.00/O Copyright (O 1987, American Society for Microbiology Vol. 25, No. 9 In Vitro Antimicrobial Spectrum, Occurrence
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Meroponia 1g Powder for Solution for Injection or Infusion Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains meropenem trihydrate
More information